Abstract
OBJECTIVES
To identify risk factors for postherpetic neuralgia (PHN) using a validated definition of this chronic neuropathic pain syndrome,
to determine combinations of risk factors that identify patients with a high risk of developing PHN, and to examine the characteristics
of patients with subacute herpetic neuralgia, that is, pain that persists beyond the acute phase of herpes zoster but that
resolves before PHN can be diagnosed.
METHODS
The authors examined baseline and follow-up data from 965 herpes zoster patients enrolled within 72 hours of rash onset in
two clinical trials of famciclovir.
RESULTS
Univariate and multivariate analyses indicated that older age, female sex, presence of a prodrome, greater rash severity,
and greater acute pain severity made independent contributions to identifying which patients developed PHN. Patients with
subacute herpetic neuralgia who did not develop PHN were significantly younger and had less severe acute pain than PHN patients
but were significantly more likely to have severe and widespread rash than patients without persisting pain.
CONCLUSIONS
The independent contributions to the prediction of PHN made by older age, female sex, presence of a prodrome, greater rash
severity, and greater acute pain severity suggest that these risk factors reflect different mechanisms that each contribute
to the development of PHN. Subacute herpetic neuralgia that does not progress to PHN may reflect peripheral tissue damage
and inflammation caused by a particularly severe or widespread rash.
Links
Authors
Jung BF, Johnson RW, Griffin DR, Dworkin RH
Institution
University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.
Source
Neurology 62:9 2004 May 11 pg 1545-51MeSH
2-AminopurineAge Factors
Antiviral Agents
Double-Blind Method
Exanthema
Female
Follow-Up Studies
Herpes Zoster
Humans
Multivariate Analysis
Neuralgia
Pain Measurement
Risk Factors
Severity of Illness Index
Sex Factors
Zoster Sine Herpete
Pub Type(s)
Clinical TrialJournal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
15136679
Log In

